Evaluation of the Advancing Developmental and Epileptic Encephalopathy Treatment Pipeline


Developmental and Epileptic Encephalopathy (DEE) is a term used to describe a category of severe epilepsies that are marked by severe developmental delays or possibly the loss of developmental skills in addition to seizures that are frequently drug-resistant. Cognitive processes are significantly impacted by seizures, interictal epileptiform activity, and the neurobiological basis of epilepsy in Developmental and Epileptic Encephalopathy. The onset of DEEs, which are also linked to gene variations, typically occurs in infancy. The time of brain maturation during which the seizures occur, which in turn depends on other factors, such as underlying pathology, genetic susceptibility factors, and seizure triggers, has an impact on cognitive function to some extent (e.g., febrile illness). While seizures are not always a direct cause of cognitive impairments, it is crucial to understand that seizures can potentially contribute to the development of cognitive impairments.


Neonatal-onset epileptic encephalopathy, infantile epileptic encephalopathy, and early childhood syndromes include early myoclonic encephalopathy, Ohtahara syndrome, West syndrome, Dravet syndrome (severe myoclonic epilepsy in infancy), Lennox-Gastaut syndrome (LGS), Landau-Kleffner syndrome (LKS), epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS).

Developmental and Epileptic Encephalopathy Market Insights

Developmental and epileptic encephalopathy (DEE) market dynamics are likely to evolve over the next few years as a result of advancements in diagnosis techniques, increased disease awareness, increased global healthcare spending, and the anticipated introduction of novel medicines. Important companies including Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Questcor Pharmaceuticals, and Mallinckrodt Pharmaceuticals, as well as Xenon Pharmaceuticals, Longboard Pharmaceuticals, Stoke Therapeutics, Takeda/Ovid Therapeutics, SK Life Science, Neurocrine Biosciences, Praxis Precision Medicines, and Jazz Pharmaceuticals.

Current Developmental and Epileptic Encephalopathy Treatment Landscape

The technique for treating epileptic encephalopathy is similar to that of treating pediatric epilepsy. Based on the epilepsy syndrome type, the most suitable anti-epileptic therapy is chosen. Despite the widespread usage of anti-seizure drugs, some types of seizures are typically challenging to manage. It serves as the main method of controlling epileptic seizures and is almost typically the initial class of treatment drugs. Prednisone or Adrenocorticotropic hormone (ACTH) steroid medication has proven beneficial for some kids. When medications are ineffective, patients may also be advised to try the ketogenic diet or a vagus nerve stimulator.


The first oral prescription cannabis formulation produced by GW Pharmaceuticals is called Epidiolex (Cannabidiol), which was created by Jazz Pharmaceuticals. It was formerly known as GWP42003-P and is also referred to as Epidyolex in Europe. It belongs to a brand-new class of antiepileptic drugs that work through a distinct mechanism. For the treatment of LGS or Dravet syndrome-related seizures in patients 2 years of age and older, it has received approval in the US and Europe. Cannabidiol, the active component of Epidiolex, is the first medication approved by the FDA that contains a refined medicinal compound derived from marijuana (CBD).


The FDA has also approved Biocodex's Diacomit (Stiripentol) for the treatment of Dravet syndrome-related seizures in patients 2 years of age and older receiving clobazam. It is an innovative anti-epileptic medication developed by Biocodex and authorized in August 2018.

Unmet Needs in Developmental and Epileptic Encephalopathy Treatment Domain

The diagnosis of rare epileptic syndromes including LGS, Dravet Syndrome, and CDKL5 deficient disorder can be difficult as the condition progresses since they are exceedingly complicated and heterogeneous disorders with various etiologies. Additionally, there are no established guidelines for the detection and management of comorbidities in rare epilepsies. Although they only treat the symptoms of Developmental and Epileptic Encephalopathy and do not deal with the disease's fundamental etiology, anti-seizure medications are now the gold standard of care. For the majority of kinds of developmental and epileptic encephalopathies, there are also no approved treatments, and off-label usage is linked to subpar outcomes in terms of safety and tolerability. Additionally, approved medications like Fintepla and Ztalmy may have substantial treatment costs.

Way Ahead

The recent FDA approval of Ztalmy, the first legal treatment for CDKL5 Deficiency Disorder, in the United States has helped the market for Developmental and Epileptic Encephalopathy develop. Only a few therapies are available in the Developmental and Epileptic Encephalopathy market at the moment. Further R&D development will be used to bridge the gap in licensed drugs caused by the dearth of numerous approved therapeutics. New medications with better seizure control could have a positive effect on DEE treatment options and patient quality of life. Epidiolex and Fintepla continue to grow their prescriber bases and attract new prescribers as a result of their strong adoption. Pharmaceutical companies don't seem to have fully examined the Developmental and Epileptic Encephalopathy market as of yet, giving the industry a large opportunity to seize the prospective market space.

Related Reports: 

Diagnostic Imaging Equipment Market

 

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

 

Invasive Candidiasis Market

 

"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.

 

Sialidosis Market 

 

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Filgrastim Biosimilar Insight

 

DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Pain Management Devices Market

 

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 

Latest Reports by DelveInsight

Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market |  Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market


To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

https://www.delveinsight.com/consulting/competitive-intelligence-services


Also, take a glance at the Blogs by DelveInsight:

Comments

Post a Comment

Popular posts from this blog

Johnson & Johnson’s Visionary Role in Addressing Unmet Needs in Oncology

Image
Bristol Myers Squibb (BMS) has established itself as a trailblazer in the Molecular Glues market , leading innovation in this cutting-edge therapeutic space. Molecular glues are small molecules that facilitate protein-protein interactions, often targeting proteins once considered "undruggable." Their transformative potential is most evident in oncology, where BMS is harnessing this technology to redefine treatment for diseases like Multiple Myeloma. Bristol Myers Squibb — Dominating the Molecular Glue Sector With its stronghold in the molecular glues landscape , BMS has gained a competitive edge by leveraging its robust pipeline and pioneering research. The company’s molecular glue, CC-92480, developed to treat Multiple Myeloma, exemplifies the potential of this technology to degrade specific proteins and halt cancer progression. Its continued advancements in molecular glues demonstrate BMS’s dedication to reshaping the molecular glues competitive landscape . BMS's domina...
Read more

Nerve Sheath Neoplasms Market Trends Analysis, Growth Opportunities and Challenges, Clinical Activities, Leading Companies, Emerging Therapies, and Epidemiology Forecast

Image
Electrical messages are sent from your brain to your body through your nerves. They consist of collections of nerve cells. The layers of protecting tissues surrounding the cells, bundles, and nerves act as insulation and speed up the electrical signal transmission. These insulating layers are where nerve sheath cancers develop. These layers consist of: Schwann Cells Endoneurium Perineurium The prevalence of benign nerve sheath tumors is low. Ages 50 to 60 are the most typical range for schwannoma occurrence. Most frequently, neurofibromas affect persons between the ages of 20 and 40. Typically, plexiform neurofibromas appear before the age of five. Only one in ten million people worldwide are affected by malignant peripheral nerve sheath tumors each year. DelveInsight’s “ Nerve Sheath Neoplasms Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nerve Sheath Neoplasms, historical and forecasted epidemiology as well as the Nerve Sheat...
Read more

Pleural Effusion Treatment Devices Pleural Effusion Treatment Devices Market report from DelveInsight provides an in-depth analysis of Pleural Effusion Treatment Devices, as well as historical and forecasted market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some Key Highlights from Pleural Effusion Treatment Devices Market Report: The underlying cause of the pleural effusion, whether breathing is impacted, and whether it is treatable efficiently all determine how serious the illness is. Heart failure, pneumonia, and viral infections are among the pleural effusion causes that are adequately treated or managed. Therapy of related mechanical issues and treatment of the underlying cause of the pleural effusion are two variables that need to be considered. Pleural Effusion Treatment Devices market is segmented based on Product Type, By Applications, and End-user. Major players which are active in the Pleural Effusion Treatment Devices market include - Pixelenergy, HEYER Medical AG, Biometrix, Redax, B. Braun Melsungen AG, OAKWORKS® Medical, Bıçakcılar Medical Equipment AS, Smiths Medical, and others. Request sample @ Pleural Effusion Treatment Devices Market Insights The market report on Pleural Effusion Treatment Devices includes an overview of the industry and a PEST Analysis. The report also examines market drivers, market constraints, and unmet medical needs to identify the greatest prospects and analyze the market's underlying potential. Pleural Effusion Treatment Devices Overview The accumulation of extra fluid between the layers of the pleura outside the lungs is known as a pleural effusion, also known as "water on the lungs." The pleura, tiny membranes that line the chest cavity and the lungs, help lubricate and assist breathing. The pleura typically contains a tiny amount of fluid. Some pleural effusion patients experience no symptoms, and the illness is only identified on a chest x-ray that is taken for another cause. Due to the illness or condition that has led to the effusion, the patient may experience unrelated symptoms. Pleural Effusion Treatment Devices Market Pleural Effusion Treatment Devices are categorized By Product (Pleural Effusion Devices- Left Pleural Effusion Devices (LVAD), Percutaneous Pleural Effusion Devices (PVAD), Biventricular Pleural Effusion Devices (BIVAD), Pleural Effusion Devices), By Type (Implanted Pleural Effusion Treatment Devices, Extracorporeal Pleural Effusion Treatment Devices), By Therapy (Bridge-To-Transplant (BTT), Bridge-To-Candidacy (BTC), Destination Therapy (DT)), By End-User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers) The Global Pleural Effusion Treatment Devices market is expected to grow with a significant CAGR of to reach a marvelous growth in overall market size. Know more about medical devices @ Pleural Effusion Treatment Devices Market Outlook Pleural Effusion Treatment Devices Key Companies Pixelenergy HEYER Medical AG Biometrix Redax B. Braun Melsungen AG OAKWORKS® Medical Bıçakcılar Medical Equipment AS Smiths Medical Pleural Effusion Treatment Devices Market Drivers Growing number of neurological diseases Increasing Pediatric infection population Technological advancements in product development Pleural Effusion Treatment Devices Market Barriers High product pricing Stringent Regulatory Process Pleural Effusion Treatment Devices Unmet Needs Lengthy product approval process Get more insights @ Pleural Effusion Treatment Devices Major Players Scope for the Report Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan) Study Period: 2019-27 Pleural Effusion Treatment Devicess Key Companies: Pixelenergy, HEYER Medical AG, Biometrix, Redax, B. Braun Melsungen AG, OAKWORKS® Medical, Bıçakcılar Medical Equipment AS, Smiths Medical, among others. Tools Used: PEST Analysis Know more about report offerings @ Pleural Effusion Treatment Devices Market Related Reports: Laron Syndrome Pipeline "Laron Syndrome Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Laron Syndrome market. A detailed picture of the Laron Syndrome pipeline landscape is provided, which includes the disease overview and Laron Syndrome treatment guidelines. Laron Syndrome Epidemiology DelveInsight's 'Laron Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Laron Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Diagnostic Imaging Equipment Market Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases. Invasive Candidiasis Market "DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW. Sialidosis Market DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Filgrastim Biosimilar Insight DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Pain Management Devices Market Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 Latest Reports by DelveInsight Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market To know more about our Competitive Services, Click here: Pharma Competitive Intelligence https://www.delveinsight.com/consulting/competitive-intelligence-services Also, take a glance at the Blogs by DelveInsight: How Metaverse is Set to Transform the Healthcare Dynamics? Role of Mobile Technology in Hemophilia Management How 3D Bioprinting Technology is Revolutionizing the Healthcare Industry? How Cloud Computing is Transforming the Healthcare Industry Dynamics?

Image
  Pleural Effusion Treatment Devices Pleural Effusion Treatment Devices Market report from DelveInsight provides an in-depth analysis of  Pleural Effusion Treatment Devices, as well as historical and forecasted market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some Key Highlights from Pleural Effusion Treatment Devices Market Report : The underlying cause of the pleural effusion, whether breathing is impacted, and whether it is treatable efficiently all determine how serious the illness is. Heart failure, pneumonia, and viral infections are among the pleural effusion causes that are adequately treated or managed. Therapy of related mechanical issues and treatment of the underlying cause of the pleural effusion are two variables that need to be considered. Pleural Effusion Treatment Devices market is segmented based on Product Type, By Applications, and End-user. Major players which are active in the Pleural Effusion Tre...
Read more